<bill session="116" type="s" number="1169" updated="2022-11-01T19:47:18Z">
  <state datetime="2019-04-11">REFERRED</state>
  <status>
    <introduced datetime="2019-04-11"/>
  </status>
  <introduced datetime="2019-04-11"/>
  <titles>
    <title type="display">Ensuring Timely Access to Generics Act of 2019</title>
    <title type="short" as="introduced">Ensuring Timely Access to Generics Act of 2019</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.</title>
  </titles>
  <sponsor bioguide_id="G000562"/>
  <cosponsors>
    <cosponsor bioguide_id="B001267" joined="2019-04-11"/>
    <cosponsor bioguide_id="C001075" joined="2019-04-11"/>
    <cosponsor bioguide_id="C001096" joined="2019-05-07"/>
    <cosponsor bioguide_id="S001181" joined="2019-04-11"/>
  </cosponsors>
  <actions>
    <action datetime="2019-04-11">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-04-11" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="2455" relation="identical"/>
    <bill session="116" type="s" number="3384" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative remedies"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government information and archives"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-12T19:03:33Z" status="Introduced in Senate">Ensuring Timely Access to Generics Act of 2019

This bill requires the Food and Drug Administration (FDA) to consider certain factors in determining whether a petition is submitted for the primary purpose of delaying the approval of a drug application.

The FDA must (1) publish a list of petitions that were submitted with an intent to delay, and (2) establish procedures to refer such petitions to the Federal Trade Commission.

The FDA may establish a timeline for submitting petitions.</summary>
</bill>
